(GMAB) Genmab - Ratings and Ratios
Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0010272202
GMAB: Antibodies, Cancers, Medications, Treatments, Pharmaceuticals
Genmab A/S is a leading biotechnology company based in Copenhagen, Denmark, specializing in the development of innovative antibody-based therapies. The company focuses primarily on cancer treatments but also addresses other diseases. Its product portfolio includes EPKINLY and TEPKINLY, which are used for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Tivdak is another key product targeting recurrent/metastatic cervical cancer. Genmabs robust pipeline includes promising candidates such as Epcoritamab for various B-cell malignancies and tisotumab vedotin for solid tumors. Additionally, the company collaborates with major pharmaceutical entities like AbbVie and Pfizer, enhancing its research and development capabilities.
Genmab has recently expanded its therapeutic reach with DARZALEX/DARZALEX FASPRO for multiple myeloma and light-chain Amyloidosis, and RYBREVANT for NSCLC. Their pipeline also includes next-generation therapies like Acasunlimab and Rinatabart Sesutecan, targeting solid tumors and ovarian cancer respectively. The companys commitment to innovation is evident through its partnerships with BioNTech and Novartis, driving advancements in cancer and autoimmune diseases. Genmabs financial health is robust, supported by a strong market capitalization and efficient operations, making it a notable player in the biotech industry.
Additional Sources for GMAB Stock
GMAB Stock Overview
| Market Cap in USD | 12,294m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception |
GMAB Stock Ratings
| Growth Rating | -42.0 |
| Fundamental | 76.8 |
| Dividend Rating | 0.0 |
| Rel. Strength | -28.1 |
| Analysts | - |
| Fair Price Momentum | 1149.21 DKK |
| Fair Price DCF | 2622.33 DKK |
GMAB Dividends
No Dividends PaidGMAB Growth Ratios
| Growth Correlation 3m | -65.8% |
| Growth Correlation 12m | -89.2% |
| Growth Correlation 5y | -43.9% |
| CAGR 5y | -3.92% |
| CAGR/Max DD 5y | -0.06 |
| Sharpe Ratio 12m | 0.14 |
| Alpha | -38.10 |
| Beta | 0.336 |
| Volatility | 42.45% |
| Current Volume | 105.7k |
| Average Volume 20d | 229k |
As of April 26, 2025, the stock is trading at DKK 1347.00 with a total of 105,740 shares traded.
Over the past week, the price has changed by +3.78%, over one month by +1.89%, over three months by -10.59% and over the past year by -29.68%.
Yes, based on ValueRay Fundamental Analyses, Genmab (CO:GMAB) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 76.82 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GMAB as of April 2025 is 1149.21. This means that GMAB is currently overvalued and has a potential downside of -14.68%.
Genmab has no consensus analysts rating.
According to ValueRays Forecast Model, GMAB Genmab will be worth about 1257.2 in April 2026. The stock is currently trading at 1347.00. This means that the stock has a potential downside of -6.66%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 2086.7 | 54.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1257.2 | -6.7% |